Skip to content

Vir Biotechnology

US · VIR #2824 by market cap Listed 2019
11.52 -0.08 -0.69%
Live - 5344 symbols - heartbeat 288s ago · 2026-10-08 08:30
Pre-market 11.85 +2.86%
After-hours 11.52 0.00%
Overnight 11.64 +1.04%
Market cap
1.95B
P/B
1.98
EPS
-3.16
Reader sentiment Are you bullish or bearish on VIR?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/4/16
  • BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15
    Market Newswire · 2026/8/8
  • Rating change
    BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/5/14
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
    SEC · 2026/5/29
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
    SEC · 2025/6/3
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.
    SEC · 2025/2/26
  • Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/9/29
  • Rating change
    A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30
    Market Newswire · 2026/8/6
  • Rating change
    A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30
    Market Newswire · 2026/8/7
  • Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17
    Market Newswire · 2026/9/30
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
    TipRanks · 2026/6/11
  • Rating change
    Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/6/1
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
    SEC · 2024/6/4
  • Rating change
    Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27
    Market Newswire · 2026/6/11
  • Rating change
    A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30
    Market Newswire · 2026/5/8
  • Rating change
    Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating
    Market Newswire · 2026/5/27
  • Company notice
    Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.
    SEC · 2024/4/3
  • H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/9/22
  • Rating change
    Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23
    Market Newswire · 2026/5/8
  • Insiders Of Vir Biotechnology Make A Tidy Sum Selling At US$8.85
    Simply Wall St · 2026/8/28

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:30:00 · For reference only, not investment advice and not tailored to your situation.